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Abstract
Background: Brentuximab vedotin is a CD30-directed antibody-drug conjugate. Retreatment with brentuximab
vedotin monotherapy was investigated in patients with CD30-positive Hodgkin lymphoma (HL) or systemic
anaplastic large cell lymphoma (ALCL) who relapsed after achieving complete or partial remission (CR or PR) with
initial brentuximab vedotin therapy in a previous study (ClinicalTrials.gov NCT00947856).
Methods: Twenty-one patients with HL and 8 patients with systemic ALCL were retreated; 3 patients with systemic
ALCL were retreated twice. Patients generally received brentuximab vedotin 1.8 mg/kg intravenously approximately
every 3 weeks over 30 minutes as an outpatient infusion. The primary objectives of this study were to assess safety
and to estimate antitumor activity of brentuximab vedotin retreatment.
Results: The objective response rate was 60% (30% CR) in HL patients and 88% (63% CR) in systemic ALCL patients.
The estimated median duration of response for patients with an objective response was 9.5 months (range, 0.0+ to
28.0+ months) at the time of study closure. Of the 19 patients with objective response, 7 patients had not had an
event of disease progression or death at the time of study closure; duration of response for these patients ranged
from 3.5 to 28 months. Of the 11 patients with CR, 45% had response durations of over 1 year.
Adverse events (AEs) occurring in ≥25% of patients during the retreatment period were generally similar in type
and frequency to those observed in the pivotal trials of brentuximab vedotin monotherapy, with the exception of
peripheral neuropathy, which is known to have a cumulative effect. Grade 3 or higher events were observed in 48%
of patients; these were generally transient and managed by dose modifications or delays. Deaths due to AEs
occurred in 3 HL patients; none were considered to be related to brentuximab vedotin retreatment.
Discussion: With the exception of a higher rate of peripheral motor neuropathy, retreatment with brentuximab
vedotin was associated with similar side effects seen in the pivotal trials.
Conclusions: Retreatment with brentuximab vedotin monotherapy is associated with response rates in 68% (39%
CR) of patients with relapsed HL and systemic ALCL.
Trial registration: United States registry and results database ClinicalTrials.gov NCT00947856.
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Background
Brentuximab vedotin (ADCETRIS®) is an antibody-drug
conjugate composed of a CD30-targeted chimeric
monoclonal antibody (cAC10) covalently linked, via a
protease-cleavable linker, to the microtubule-disrupting
agent monomethyl auristatin E. Results from phase
2 pivotal trials of single-agent brentuximab vedotin
(1.8 mg/kg) demonstrated an objective response rate
(ORR) of 75% (34% complete remission [CR]) in Hodgkin
lymphoma (HL) patients and 86% (57% CR) in systemic
anaplastic large cell lymphoma (ALCL) patients [1,2].
The median duration of response for patients with an
objective response was 6.7 months for HL patients and
12.6 months for systemic ALCL patients and the median
duration of response for patients with CR was 20.5 months
and 13.2 months, respectively [1,2]. Long-term follow-
up date for these patients continue to show durable CR
[3,4]. The safety profile was associated with manageable
toxicities.
Physicians caring for HL and systemic ALCL patients
who initially respond to brentuximab vedotin and then
subsequently progress face a conundrum. Their choices
range from aggressive regimens that enable transplant-
ation to palliative measures with a goal of maximizing a
patient’s quality of life. It was hypothesized that these
patients might benefit from a second course of brentuxi-
mab vedotin.
This phase 2 study was designed to investigate the
safety and antitumor activity of brentuximab vedotin
when administered as a retreatment option for patients
who had previously achieved an objective response
(complete or partial remission [PR]) with prior brentuxi-
mab vedotin treatment. Secondary objectives were to as-
sess the duration of tumor control, progression-free and




Eligibility criteria for this study included patients who
previously experienced a CR or PR with brentuximab
vedotin, discontinued treatment while in remission, and
subsequently experienced disease progression or relapse.
Patients who received an allogeneic stem cell transplant
(SCT) were eligible if they were >100 days from trans-
plant and had no evidence of cytomegalovirus by poly-
merase chain reaction.
Study design and treatment
This was an open-label, multicenter, international, phase
2 study of retreatment in patients who had responded to
brentuximab vedotin monotherapy on a previous clinical
trial. This report summarizes results of retreatment for
patients with HL or systemic ALCL.
Patients in the retreatment arm were treated at 10
sites in the United States and 1 site in France. Patients
began enrolling in July 2009. An interim analysis was
performed on a subset of patients in the retreatment
arm who had enrolled in the study and signed informed
consent by April 2012. The Sponsor stopped the study
in January 2013 because the pool of potential retreat-
ment patients from prior trials was projected to be min-
imal. The final retreatment analysis was performed after
study closure in March 2013. These data are presented
in this article.
The protocol for this study was designed in accord-
ance with the general ethical principles outlined in the
Declaration of Helsinki. The conduct of all aspects of
the study, including methods for obtaining informed
consent, was also in accordance with principles enunci-
ated in the declaration. The study was registered on
ClinicalTrials.gov (NCT00947856) and the protocol was
approved by the institutional review board or independ-
ent ethics committee for each study site; all patients pro-
vided written informed consent before any study-specific
procedures began.
Retreatment with brentuximab vedotin monotherapy
was administered intravenously over approximately
30 minutes on Day 1 of each 21-day treatment cycle
(i.e., one dose is equal to one cycle), although investiga-
tors may have adjusted the dosing schedule as appropri-
ate to manage side effects. Dosing was based on the
patient’s weight, as measured according to institutional
standards. The starting dose was to be 1.8 mg/kg; how-
ever, if for any reason a patient entered the study after
receiving 1.2 mg/kg every 3 weeks on a prior trial, their
dose continued to be 1.2 mg/kg. Patients were allowed
to continue receiving treatment until disease progres-
sion, unacceptable toxicity, or study closure occurred;
no maximum duration of therapy was specified in the
protocol.
Study assessments
The primary objective of the study was to evaluate the
safety and antitumor activity of retreatment with bren-
tuximab vedotin. The assessment of safety during the
course of the study consisted of the surveillance and re-
cording of adverse events (AEs), including any serious
AEs (SAEs), recording of concomitant medication, and
measurements of laboratory tests. A Safety Monitoring
Committee assessed the safety and antitumor activity
data periodically during the study.
Determination of antitumor activity was based on inves-
tigator assessment of response. The restaging schedule
was performed per institutional standard of care; treat-
ment decisions were based on the investigator assessment
of response. Response was assessed using computed tom-
ography (CT) and positron emission tomography (PET)
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according to the Revised Response Criteria for Malignant
Lymphoma [5]. B symptoms (fever, night sweats, and
weight loss) were also captured.
Plasma and serum samples for brentuximab vedotin
concentration and immunogenicity evaluation were ob-
tained prior to brentuximab vedotin administration in
Cycles 1 and 2, and at the end of treatment visit.
Patients who discontinued treatment remained in
study follow-up unless they withdrew consent and were
contacted at least every 3 months until death or study
closure. Patients who had a CR or PR in retreatment
and then progressed after discontinuing therapy may
have been re-enrolled and retreated more than once in
this study at the discretion of the investigator.
Adverse events were classified using the Medical Dic-
tionary for Regulatory Activities (MedDRA) version 14 and
graded using the National Cancer Institute (NCI) Common
Terminology Criteria for Adverse Events (CTCAE) Version
3.0; laboratory abnormalities were also graded using the
NCI CTCAE. Concomitant medications were coded
using World Health Organization (WHO) Drug (Version
June 2009).
Statistical analysis
Safety of retreatment with brentuximab vedotin was
summarized descriptively for all patients by the type,
incidence, severity, seriousness, and relatedness of AEs
and laboratory abnormalities, including the incidence
of ATA.
Antitumor activity was evaluated for patients with
post-baseline response measurements by calculating the
ORR, defined as the proportion of patients with CR or
PR, and its two-sided 95% exact confidence interval (CI).
Secondary objectives included the CR rate, duration of
response, progression-free survival (PFS), and overall
survival (OS). The duration of response, PFS, and OS
were estimated using Kaplan-Meier methodology.
Results
Patients
Twenty-nine patients with HL (N = 21) or systemic
ALCL (N = 8) were retreated in this study. Demographic
and disease characteristics are presented in Table 1. The
median age of HL and systemic ALCL patients was
33 years (range, 16 to 72 years). ECOG performance sta-
tus was 0 or 1 in 93% of patients. Patients were a median
of 4.3 years (range, <1 to 8.4 years) from time of disease
diagnosis to retreatment. The median time from the last
dose of brentuximab vedotin on the most recent study
to the first dose of brentuximab vedotin on the retreat-
ment study was 8 months (range, 2 to 45 months).
Patients had at least 2 prior systemic therapies (median,
4 systemic therapies; range, 2 to 12 systemic therapies), in-
cluding at least one prior course of brentuximab vedotin
therapy (Table 1). With the exception of 1 patient who
had stable disease, all patients had a prior objective re-
sponse to brentuximab vedotin. The patient had a best re-
sponse of stable disease on the previous study. This
patient had received 1.2 mg/kg every week for 3 weeks
but missed at least 3 doses of study drug due an AE of
neutropenia; the treating physician felt that the dosing
schedule was suboptimal and an exemption was granted
for the patient to enter the retreatment study. Six patients
(21%) received intervening systemic therapies between the
most recent prior brentuximab vedotin treatment and







(N = 21) (N = 8)
Age, year
Median (range) 30 (16, 65) 51.5 (24, 72)
Gender, no. (%)
Male 10 (48) 4 (50)
Female 11 (52) 4 (50)
Race, no. (%)
Other 0 (0) 1 (13)
Black or African American 2 (10) 2 (25)
White 19 (90) 5 (63)
ECOG Performance Status, no. (%)
0 8 (38) 3 (38)
1 12 (57) 4 (50)
2 1 (5) 1 (13)
Initial diagnosis, no. (%)
ALK positive – 3 (38)
ALK negative – 5 (63)
Number of prior systemic therapiesa
Median (range) 4 (2, 12) 3 (2, 6)
Time between last brentuximab vedotin
dose on prior study and first dose of
retreatment (months)
Median (range) 11.4 (4, 45) 4.7 (2, 15)
Number of patients with intervening
systemic therapies, n (%)
6 (21) 0
Best response, n/n (%)
Stable disease 1 (17) –
Progressive disease 4 (67) –
Unknown/other 1 (17) –
Disease status relative to most recent
prior therapy, n (%)
Refractory 5 (24) 0
Relapse after response 16 (76) 8 (100)
aIncludes any prior brentuximab vedotin treatment.
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retreatment, including one patient who received commer-
cial brentuximab vedotin. The best response achieved with
the intervening systemic therapy was progressive disease
(67%), stable disease (17%), or unknown/other (17%) for
the 1 patient who had received commercial brentuximab
vedotin treatment.
Efficacy
The efficacy evaluable population included 28 patients
(20 HL and 8 systemic ALCL patients), as 1 HL patient
did not have post-baseline response assessments. The
ORR for HL and systemic ALCL retreatment patients
was 68% (95% CI; 47.6, 84.1), with a CR rate of 39%
(95% CI; 21.5, 59.4) (Table 2). The ORR was 60% (30%
CR) for HL patients and 88% (63% CR) for systemic
ALCL patients. The majority of patients (81%) who re-
ceived brentuximab vedotin retreatment experienced re-
duction in measurable tumor volume (Figure 1).
The estimated median duration of response for patients
with an objective response was 9.5 months (range, 0.0+
to 28.0+ months): this median duration was 9.2 months
(range, 0.0+ to 19.5+ months) for HL patients and
12.3 months (range, 6.6 to 28.0+ months) for systemic
ALCL patients. For patients with CR, the estimated median
duration of response was 12.3 months (range, 7.4 to
14.2 months): this median duration was 9.4 months (range,
1.7 to 14.2 months) for HL patients and 12.9 months
(range, 7.4 to 28.0+ months) for systemic ALCL patients.
Twelve patients with objective response had an event of
disease progression or death at the time of study closure,
including 8 patients who had a best response of CR. The
median PFS for HL and systemic ALCL patients was 9.9
and 12.9 months, respectively (Figure 2). The median OS
had not yet been reached at the time of study closure and
further long-term follow-up is not planned (Figure 3).
Ten patients had B symptoms at baseline. Resolution
of all B symptoms occurred in 6 patients and occurred,
on average, 5 weeks after initiation of retreatment with
brentuximab vedotin. Of these 6 patients, 4 patients had
an objective response and 2 patients had stable disease.
Two patients who were retreated with brentuximab
vedotin achieved CR and subsequently received an allo-
geneic SCT. One patient with systemic ALCL had a CR
after frontline treatment with brentuximab vedotin com-
bined with CHOP and then relapsed; retreatment with
brentuximab vedotin enabled a successful allogeneic
SCT with a subsequent continuing duration of response
greater than 1 year. One Stage IV HL patient with mul-
tiple prior therapies (doxorubicin, bleomycin, vinblastine,
and dacarbazine; ifosfamide, carboplatin, and etoposide;
gemcitabine) had a best response of PR with initial bren-
tuximab vedotin treatment and then received an allogen-
eic SCT; this patient subsequently relapsed and was
retreated with brentuximab vedotin. After achieving CR
with retreatment, the patient had another allogeneic SCT
with a duration of response of approximately 9 months
prior to subsequent progression.
Safety
Twenty-seven of the 29 patients started retreatment
at 1.8 mg/kg and 2 patients started retreatment at
1.2 mg/kg (dose reduced in a prior study due to man-
agement of AEs). The median number of brentuximab
vedotin cycles was 7 (range, 2 to 37 cycles). The median
duration of retreatment was 5 months (range, 1 to
38 months).
Treatment-emergent AEs that occurred in ≥25% of pa-
tients were peripheral sensory neuropathy (59%); fatigue
and nausea (41% each); diarrhea (38%); and arthralgia,
headache, peripheral motor neuropathy, and pyrexia
(28% each) (Table 3). Adverse events leading to retreat-
ment discontinuation occurred in 9 patients (31%); 6 pa-
tients discontinued retreatment due to either peripheral
sensory neuropathy (5 patients) or peripheral motor
neuropathy (1 patient).






(N = 20) (N = 8)
Objective response rate (CR + PR) 12 (60) 7 (88)
Best clinical responsea
Complete remission 6 (30) 5 (63)
Partial remission 6 (30) 2 (25)
Stable disease 4 (20) 0
Progressive disease 4 (20) 1 (13)
95% CI for ORRb 36.1, 80.9 47.3, 99.7
95% CI for CR rateb 11.9, 54.3 24.5, 91.5
Duration of objective response for
patients with OR, monthsc
12 (60) 7 (88)
Median (95% CI)d 9.2 (2.1, −) 12.3 (6.6, −)
Duration of response for patients with
CR, monthsc
6 (30) 5 (63)
Median (95% CI)d 9.4 (1.7, 14.2) 12.9 (7.4, −)
Progression-free survival, monthse
Median (95% CI)d 9.9 (3.4, 13.4) 12.9 (1.4, 18.5)
Overall survival, monthse
Median (95% CI)d - (11.4, −) - (3.3, −)
Analysis excludes the second retreatment for 3 systemic anaplastic large cell
lymphoma patients.
aBest response (according to Cheson 2007) prior to the start of any new
antitumor treatment, exclusive of stem cell transplant.
bTwo-sided 95% exact confidence interval (CI), computed using the
Clopper-Pearson method (1934).
cDuration of response is calculated from the earliest occurrence of either
complete or partial remission.
dComputed using the log-log transformation method of Collett (1994).
e As estimated using Kaplan-Meier methods.
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Events that were ≥Grade 3 occurred in 48% of patients
and event terms occurring in ≥10% of patients were
anemia (17%); fatigue (14%); and hyperglycemia, hypo-
phosphatemia, and thrombocytopenia (10% each). Ser-
ious AEs were defined as AEs that were fatal, life
threatening, disabling/incapacitating, medically signifi-
cant, or led to hospitalization or a congenital anomaly
or birth defect and occurred in 8 patients. Of these,
Grade 5 (fatal) events occurred in 3 HL patients and were
due to respiratory failure, graft versus host disease, or
bronchopulmonary aspergillosis; none of these fatal events
were considered to be related to brentuximab vedotin
retreatment. Additionally, 6 patients died after the 30-day
safety follow-up period; 4 patients due to disease progres-
sion, 1 patient who experienced sepsis, and 1 patient with
an unknown etiology.
Almost half the patients who entered the study had
pre-existing peripheral neuropathy (48%) at retreatment
baseline. Treatment-emergent peripheral neuropathy events
were defined as newly occurring (not present at retreatment
Figure 1 Maximum reduction in target lesion size. Best change in the sum of the product of diameter (SPD) of target lesions achieved over
all restages. One patient with Hodgkin lymphoma had no postbaseline tumor measurements reported and is thus not included in the summary.
Analysis excludes the second retreatment for 3 systemic anaplastic large cell lymphoma patients.
Figure 2 Progression-free survival. Symbols on the plot indicate censored patients. Analysis excludes the second retreatment for 3 systemic
anaplastic large cell lymphoma patients.
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baseline) or worsening after the first dose of retreatment.
Peripheral neuropathy was observed in 69% of patients and
included peripheral sensory neuropathy, peripheral
motor neuropathy, paraesthesia, burning sensation, and
gait disturbance; severity was generally Grade 1 or 2.
Grade 3 peripheral neuropathy events occurred in 3
patients; the median time to onset of Grade 3 events
was approximately 13 months (range, 6 to 20 months).
Peripheral neuropathy events were managed with dose
modifications (delays or reductions).
Of the 28 patients with any immunogenicity results,
12 patients (43%) tested positive for ATA at any visit
during the study and 9 patients (32%) tested positive for
ATA at baseline. Six HL patients had infusion-related re-
actions; of these, 5 patients tested positive for ATA post-
baseline. Of the 11 patients with a best response of CR,
7 patients tested positive for ATA at least once during
the study. None of the 5 patients with a best response of
progressive disease tested positive for ATA at any visit.
Patients retreated more than once
Three systemic ALCL patients were retreated twice dur-
ing the study; all 3 patients were female and were 52, 53,
and 70 years of age. Safety profiles were generally similar
for both the first and second retreatment experiences.
Two patients achieved a PR with both retreatment expe-
riences and 1 patient achieved a CR with both retreat-
ment experiences. None of these patients developed
ATA during either retreatment experience.
Discussion
This open-label multicenter study evaluated the safety and
antitumor activity of retreatment with brentuximab vedo-
tin in patients with relapsed HL or systemic ALCL who
had responded previously to brentuximab vedotin therapy.
Antitumor activity was observed in 68% of HL and sys-
temic ALCL retreatment patients. At the time of study
Figure 3 Overall survival. Symbols on the plot indicate censored patients. Analysis excludes the second retreatment for 3 systemic anaplastic
large cell lymphoma patients.
Table 3 Treatment-emergent adverse events reported by
at least 20% of patients and grade 3 and higher


















17 (59) 2 (7) 0 0
Fatigue 12 (41) 3 (10) 1 (3) 0
Nausea 12 (41) 1 (3) 0 0
Diarrhea 11 (38) 0 0 0
Arthralgia 8 (28) 2 (7) 0 0




8 (28) 2 (7) 0 0
Pyrexia 8 (28) 0 0 0
Anemia 7 (24) 5 (17) 0 0
Dyspnea 7 (24) 1 (3) 1 (3) 0
Back pain 6 (21) 1 (3) 0 0
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closure, the estimated median duration of response for pa-
tients with an objective response was 9.5 months. Seven of
19 patients with an objective response were still alive and
in remission at the time of study closure; duration of re-
sponse for these patients ranged from 3.5 to 28 months.
The antitumor activity observed with retreatment is con-
sistent with the objective response rates seen in the phase
2 pivotal trials in patients with relapsed or refractory HL
(75%) and systemic ALCL (86%). In the pivotal trials, the
median duration of objective response for patients with
CR was 20.5 months for HL patients and 13.2 months for
systemic ALCL patients [1,2]; long-term follow up data
continue to show durable CR [3,4]. Unlike the pivotal tri-
als, patients in the retreatment study were scanned at in-
tervals per institutional standard of care; thus, remission
durability is less precise.
Upon retreatment, observed AEs (occurring in ≥25%
of patients), including peripheral sensory neuropathy, fa-
tigue, nausea, diarrhea, arthralgia, headache, peripheral
motor neuropathy, and pyrexia, were typically managed
with dose modifications and were primarily Grade 1 or 2
in severity. The rates for AEs reported in patients
retreated with brentuximab vedotin were generally con-
sistent with those observed in the pivotal phase 2 trials,
with the exception of peripheral motor neuropathy seen
in a higher percentage of patients (28% total versus 11%
for HL patients and 5% for systemic ALCL patients in
the pivotal trials); these events were primarily Grade 1
or 2 in severity [1,2].
There is precedent in lymphoma for retreatment with
an effective targeted agent as retreatment data with ri-
tuximab in patients with relapsed low-grade or follicular,
CD20-positive B-cell non-Hodgkin lymphoma resulted
in an ORR of 38% for retreatment [6]. In the current
study, 60% of patients with HL and 88% of patients with
systemic ALCL responded to retreatment with brentuxi-
mab vedotin, often despite a short remission duration
(less than 3 months) following initial brentuximab vedo-
tin treatment.
Whether allogeneic transplantation should be employed
after a failed autograft is a subject of considerable uncer-
tainty. In this present study, complete remissions with a
median duration of over 1 year were obtained by 45% of
retreatment patients, 2 of whom subsequently received
allogeneic SCT. Similarly, few allografts were performed
in the 102 patient relapsed/refractory HL pivotal trial that
led to the initial approval of brentuximab vedotin and this
approach appeared to be associated with acceptable long-
term outcomes. In a 3-year follow-up analysis, 50% of pa-
tients remained alive and 18 of all 102 treated patients
remained in remission per investigator review [3]. In a
separate case review that evaluated brentuximab vedotin
in heavily-pretreated (5–19 prior therapies) HL patients
with recurrent disease after allogeneic SCT, 50% of
patients achieved an objective response (38% CR) [7].
However, 50% to 60% of patients who undergo allogeneic
SCT have chronic graft versus host disease, which often
represents a significant burden on their quality of life [8].
Another possibility could be retreatment with brentuxi-
mab vedotin and consideration of consolidation with allo-
geneic transplant at the time of the next remission [9].
Preliminary results from a retrospective analysis of re-
lapsed or refractory HL patients suggest that, after 2 years
of follow-up, brentuximab vedotin prior to reduced inten-
sity allogeneic hematopoietic cell transplantation may
yield prolonged disease control without a delay in engraft-
ment, increases in non-relapse mortality, or other post-
transplant complications [10]. One consideration during
retreatment is that patients should be followed closely for
peripheral sensory or motor neuropathy and dose reduc-
tions initiated as needed.
The findings from this study suggest that brentuximab
vedotin retreatment is a viable option for a relatively
young, heavily pretreated lymphoma patient population
who presently struggle with the toxic effects of serial,
palliative chemotherapeutic regimens in an attempt to
maximize quality of life.
Conclusions
In summary, retreatment with brentuximab vedotin de-
livered a second response in 68% (39% CR) of HL and
systemic ALCL patients who had previously received
treatment. With the exception of a higher rate of periph-
eral motor neuropathy, retreatment with brentuximab
vedotin was associated with similar side effects seen in
the pivotal trials.
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